Back to search results

Sacituzumab govitEcan in THYroid Cancers

Abroad (travel likely)RecruitingPHASE2

Conditions

Differentiated Thyroid Cancer · Anaplastic Thyroid Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Hospital Universitari Vall d'Hebron, Barcelona, Spain

    Contact: Study coordinator (A responsible person Designated by the sponsor) · investigacion@mfar.net · +34 93 434 44 12
    Contact: Principal Investigator (A Principal Investigator Designated by the sponsor, M.D.; Ph.D.)

  • Complexo Hospitalario Universitario de Ferrol, Ferrol, Spain

    Contact: Study coordinator (A responsible person Designated by the sponsor) · investigacion@mfar.net · +34 93 434 44 12
    Contact: Principal Investigator (A Principal Investigator Designated by the sponsor, M.D.; Ph.D.)

  • Institut Catala d´Oncologia (ICO) -Hospitalet, Hospitalet de Llobregat (Barcelona), Spain

    Contact: Study coordinator (A responsible person Designated by the sponsor) · investigacion@mfar.net · +34 93 434 44 12
    Contact: Principal Investigator (A Principal Investigator Designated by the sponsor, M.D.; Ph.D.)

  • Hospital Clínico San Carlos, Madrid, Spain

    Contact: Study coordinator (A responsible person Designated by the sponsor) · investigacion@mfar.net · +34 93 434 44 12
    Contact: Principal Investigator (A Principal Investigator Desingated by the sponsor, M.D.; Ph.D.)

  • Hospital Universitario la Paz, Madrid, Spain

    Contact: Study coordinator (A responsible person Designated by the sponsor) · investigacion@mfar.net · +34 93 434 44 12
    Contact: Principal Investigator (A Principal Investigator Designated by the sponsor, M.D.; Ph.D.)

  • Hospital Universitario Ramón y Cajal, Madrid, Spain

    Contact: Study coordinator (A responsible person Designated by the sponsor) · investigacion@mfar.net · +34 93 434 44 12
    Contact: Principal Investigator (A Principal Investigator Designated by the sponsor, M.D.; Ph.D.)

  • MD Anderson Cancer Center Madrid, Madrid, Spain

    Contact: Study coordinator (A responsible person Designated by the sponsor) · investigacion@mfar.net · +34 93 434 44 12
    Contact: Principal Investigator (A principal investigator Designated by the sponsor, M.D.; Ph.D.)

  • Hospital General Universitario Morales Meseguer, Murcia, Spain

    Contact: Study coordinator (A responsible person Designated by the sponsor) · investigacion@mfar.net · +34 93 434 44 12
    Contact: Principal Investigator (A Principal Investigator Designated by the sponsor, M.D.; Ph.D.)

  • Hospital Universitario Central de Asturias, Oviedo, Spain

    Contact: Study coordinator (A responsible person Designated by the sponsor) · investigacion@mfar.net · +34 93 434 44 12
    Contact: Principal Investigator (A Principal Investigator Designated by the sponsor, M.D.; Ph.D.)

  • H.U. Marqués de Valdecilla, Santander, Spain

    Contact: Study coordinator (A responsible person Designated by the sponsor) · investigacion@mfar.net · +34 93 434 44 12
    Contact: Principal Investigator (A Principal Investigator Designated by the sponsor, M.D.; Ph.D.)

  • Hospital Universitario Miguel Servet, Zaragoza, Spain

    Contact: Study coordinator (A responsible person Designated by the sponsor) · investigacion@mfar.net · +34 93 434 44 12
    Contact: Principal Investigator (A Principal Investigator Designated by the sponsor, M.D.; Ph.D.)
Study leads

  • Alejandro García-Alvarez, M.D.; Ph.D.

    Study Chair

    Hospital Universitario Vall d´Hebron

  • Jaume Capdevila, M.D.; Ph.D.

    Study Chair

    Hospital Universitario Vall d´Hebron

View source on ClinicalTrials.gov(opens in a new tab)